Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search
  1. NCI-F Publications

Search
  1. Year Published:

Your search returned 18 results.
User Information
Export Records
  1. 1.   Ductal Carcinoma In Situ: Detection, Diagnosis, and Characterization with Magnetic Resonance Imaging
  2. Jansen, S. A.
  3. Seminars in Ultrasound Ct and Mri. 2011, Aug; 32(4): 306-318.
  1. 2.   The p270 (ARID1A/SMARCF1) subunit of mammalian SWI/SNF-related complexes is essential for normal cell cycle arrest
  2. Nagl, N. G.; Patsialou, A.; Haines, D. S.; Dallas, P. B.; Beck, G. R.; Moran, E.
  3. Cancer Research. 2005, OCT 15; 65(20): 9236-9244.
  1. 3.   In vivo antitumor efficacy of 17-DMAG (17-dimethylaminoethylamino-17-demethoxygeldanamycin hydrochloride), a water-soluble geldanamycin derivative
  2. Hollingshead, M.; Alley, M.; Burger, A. M.; Borgel, S.; Pacula-Cox, C.; Fiebig, H. H.; Sausville, E. A.
  3. Cancer Chemotherapy and Pharmacology. 2005, AUG; 56(2): 115-125.
  1. 4.   Medroxyprogesterone acetate elevation of Nm23-H1 metastasis suppressor expression in hormone receptor-negative breast cancer
  2. Palmieri, D.; Halverson, D. O.; Ouatas, T.; Horak, C. E.; Salerno, M.; Johnson, J.; Figg, W. D.; Hollingshead, M.; Hursting, S.; Berrigan, D.; Steinberg, S. M.; Merino, M. J.; Steeg, P. S.
  3. Journal of the National Cancer Institute. 2005, MAY 4; 97(9): 632-642.
  1. 5.   Elucidation of thioredoxin as a molecular target for antitumor quinols
  2. Bradshaw, T. D.; Matthews, C. S.; Cookson, J.; Chew, E. H.; Shah, M.; Bailey, K.; Monks, A.; Harris, E.; Westwell, A. D.; Wells, G.; Laughton, C. A.; Stevens, M. F. G.
  3. Cancer Research. 2005, MAY 1; 65(9): 3911-3919.
  1. 6.   Arylthioindoles, potent inhibitors of tubulin polymerization
  2. De Martino, G.; La Regina, G.; Coluccia, A.; Edler, M. C.; Barbera, M. C.; Brancale, A.; Wilcox, E.; Hamel, E.; Artico, M.; Silvestri, R.
  3. Journal of Medicinal Chemistry. 2004, DEC 2; 47(25): 6120-6123.
  1. 7.   SJG-136 (NSC 694501), a novel rationally designed DNA minor groove interstrand cross-linking agent with potent and broad spectrum antitumor activity. Part 2: Efficacy evaluations
  2. Alley, M. C.; Hollingshead, M. G.; Pacula-Cox, C. M.; W, W. R.; Hartley, J. A.; Howard, P. W.; Gregson, S. J.; Thurston, D. E.; Sausville, E. A.
  3. Cancer Research. 2004, SEP 15; 64(18): 6700-6706.
  1. 8.   The experimental antitumor agents Phortress and Doxorubicin are equiactive against human-derived breast carcinoma xenograft models
  2. Fichtner, I.; Monks, A.; Hose, C.; Stevens, M. F. G.; Bradshaw, T. D.
  3. Breast Cancer Research and Treatment. 2004, SEP; 87(1): 97-107.
  1. 9.   Synthesis, cytotoxicity, and inhibitory effects on tubulin polymerization of a new 3-heterocyclo substituted 2-styrylquinazolinones
  2. Raffa, D.; Edler, M. C.; Daidone, G.; Maggio, B.; Merickech, M.; Plescia, S.; Schillaci, D.; Bai, R. L.; Hamel, E.
  3. European Journal of Medicinal Chemistry. 2004 39(4): 299-304.
  1. 10.   Aryl hydrocarbon receptor activation of an antitumor aminoflavone: Basis of selective toxicity for MCF-7 breast tumor cells
  2. Loaiza-Perez, A. I.; Kenney, S.; Boswell, J.; Hollingshead, M.; Alley, M. C.; Hose, C.; Ciolino, H. P.; Yeh, G. C.; Trepel, J. B.; Vistica, D. T.; Sausville, E. A.
  3. Molecular Cancer Therapeutics. 2004 3(6): 715-725.
  1. 11.   Suppression of breast cancer by chemical modulation of vulnerable zinc fingers in estrogen receptor
  2. Wang, L. H.; Yang, X. Y.; Zhang, X. H.; Mihalic, K.; Fan, Y. X.; Xiao, W. H.; Howard, O. M. Z.; Appella, E.; Maynard, A. T.; Farrar, W. L.
  3. Nature Medicine. 2004 10(1): 40-47.
  1. 12.   An expanding appreciation of the role chemokine receptors play in cancer progression
  2. Howard, O. M. Z.; Galligan, C. L.
  3. Current Pharmaceutical Design. 2004 10(19): 2377-2389.
  1. 13.   Combinatorial evolution of high-affinity peptides that bind to the Thomsen-Friedenreich carcinoma antigen
  2. Landon, L. A.; Peletskaya, E. N.; Glinsky, V. V.; Karasseva, N.; Quinn, T. P.; Deutscher, S. L.
  3. Journal of Protein Chemistry. 2003 22(2): 193-204.
  1. 14.   Phase I clinical and pharmacokinetic study of flavopiridol administered as a daily 1-hour infusion in patients with advanced neoplasms
  2. Tan, A. R.; Headlee, D.; Messmann, R.; Sausville, E. A.; Arbuck, S. G.; Murgo, A. J.; Melillo, G.; Zhai, S. P.; Figg, W. D.; Swain, S. M.; Senderowicz, A. M.
  3. Journal of Clinical Oncology. 2002 20(19): 4074-4082.
  1. 15.   New genes involved in cancer identified by retroviral tagging
  2. Suzuki, T.; Shen, H. F.; Akagi, K.; Morse, H. C.; Malley, J. D.; Naiman, D. Q.; Jenkins, N. A.; Copeland, N. G.
  3. Nature Genetics. 2002 32(1): 166-174.
  1. 16.   Nm23-H1 metastasis suppressor phosphorylation of kinase suppressor of ras via a histidine protein kinase pathway
  2. Hartsough, M. T.; Morrison, D. K.; Salerno, M.; Palmieri, D.; Ouatas, T.; Mair, M.; Patrick, J.; Steeg, P. S.
  3. Journal of Biological Chemistry. 2002 277(35): 32389-32399.
  1. 17.   Flavopiridol Induces Apoptosis of Normal Lymphoid Cells, Causes Immunosuppression, and Has Potent Antitumor Activity in Vivo Against Human Leukemia and Lymphoma Xenografts
  2. Arguello, F.; Alexander, M.; Sterry, J. A.; Tudor, G.; Smith, E. M.; Kalavar, N. T.; Greene, J. F.; Koss, W.; Morgan, C. D.; Stinson, S. F.; Siford, T. J.; Alvord, W. G.; Klabansky, R. L.; Sausville, E. A.
  3. Blood. 1998 91(7): 2482-2490.
  1. 18.   Determination of Flavopiridol (L86 8275 Nsc 649890) in Human Plasma By Reversed-Phase Liquid Chromatography With Electrochemical Detection
  2. Stinson, S. F.; Hill, K.; Siford, T. J.; Phillips, L. R.; Daw, T. W.
  3. Cancer Chemotherapy and Pharmacology. 1998 42(4): 261-265.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel